AR080292A1 - Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml - Google Patents
Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/mlInfo
- Publication number
- AR080292A1 AR080292A1 ARP110100553A ARP110100553A AR080292A1 AR 080292 A1 AR080292 A1 AR 080292A1 AR P110100553 A ARP110100553 A AR P110100553A AR P110100553 A ARP110100553 A AR P110100553A AR 080292 A1 AR080292 A1 AR 080292A1
- Authority
- AR
- Argentina
- Prior art keywords
- vitamin
- hydroxybenzoyl
- amino
- levels
- pharmaceutically acceptable
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 title 3
- 230000007812 deficiency Effects 0.000 title 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 16
- 229930003779 Vitamin B12 Natural products 0.000 abstract 14
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 14
- 235000019163 vitamin B12 Nutrition 0.000 abstract 14
- 239000011715 vitamin B12 Substances 0.000 abstract 14
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 abstract 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 10
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 abstract 8
- 229960002446 octanoic acid Drugs 0.000 abstract 8
- 150000003839 salts Chemical class 0.000 abstract 8
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 abstract 7
- 239000006186 oral dosage form Substances 0.000 abstract 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 abstract 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 5
- 229960000304 folic acid Drugs 0.000 abstract 5
- 235000019152 folic acid Nutrition 0.000 abstract 5
- 239000011724 folic acid Substances 0.000 abstract 5
- 238000010606 normalization Methods 0.000 abstract 2
- 229960005480 sodium caprylate Drugs 0.000 abstract 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 abstract 2
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Se describen los métodos para la normalizacion de los niveles de vitamina B12 en pacientes con niveles bajos de vitamina B12 y los métodos para la normalizacion de la variabilidad interindividual en el tratamiento de estos pacientes. También se describen los métodos para la reduccion de MMA (ácido metilmalonico) y/o los niveles de homocisteína, y las composiciones farmacéuticas utiles para efectuar tales cambios. Reivindicacion 1: Un método para normalizar en forma rápida los niveles de vitamina B12 en un paciente que tiene una deficiencia de vitamina B12 y un nivel promedio de vitamina B12 por debajo de 350 pg/ml, que incluye la administracion diaria durante, al menos, 15 días, de una o más formas de dosificacion oral que comprende, (i) ácido N-[8-(2-hidroxibenzoil)amino]caprílico o una sal farmacéuticamente aceptable del mismo, (ii) la vitamina B12, y, opcionalmente, (iii) el ácido folico, en donde la cantidad total diaria del ácido N-[8-(2- hidroxibenzoil)amino]caprílico o una sal farmacéuticamente aceptable del mismo es de 50 a 250 mg y la dosis diaria total de vitamina B12 es de 0,5 a 2 mg, en donde el nivel de vitamina B12 en el paciente se normaliza dentro de un plazo de 15 días. Reivindicacion 7: Un método para reducir los niveles del ácido metilmalonico (MMA (por sus siglas en idioma Inglés)) en un paciente que tiene los niveles elevados de MMA, en donde el paciente tiene un nivel de MMA de al menos 150 nmol/L, el método que comprende la administracion de una o más formas de dosificacion oral que comprende (i) ácido N[8-(2-hidroxibenzoil)amino]caprílico o una sal farmacéuticamente aceptable del mismo, (ii) la vitamina B12, y, opcionalmente, (iii) el ácido folico, en donde la cantidad total diaria de ácido N-[8-(2-hidroxibenzoil)amino]caprílico o una sal farmacéuticamente aceptable del mismo es de 50 a 250 mg y la dosis diaria total de vitamina B12 es de 0,5 a 2 mg, en donde los niveles de MMA en el paciente se normalizan dentro de los 15 días. Reivindicacion 11: Un método para reducir los niveles de homocisteína en pacientes con niveles elevados de homocisteína, en donde el paciente tiene un nivel de homocisteína de, al menos, 13 nmol/L, el método que abarca la administracion diaria de una o más formas de dosificacion oral que comprende (i) ácido 8-(N-[2-hidroxibenzoil)amino]caprílico o una sal farmacéuticamente aceptable del mismo, (ii) la vitamina B12, y, opcionalmente, (iii) el ácido folico, en donde la cantidad total diaria de ácido N-[8-(2-hidroxibenzoil)amino]caprílico] o una sal farmacéuticamente aceptable de la misma es de 50 a 250 mg y la dosis diaria total de vitamina B12 es de 0,5 a 2 mg, en donde el nivel de homocisteína en los pacientes se normaliza en un plazo de 15 días. Reivindicacion 16: Una forma de dosificacion oral que comprende: (a) vitamina B12 (b) ácido N-[8-(2-hidroxibenzoil)amino]caprílico o una sal farmacéuticamente aceptable del mismo, y (c) ácido folico. Reivindicacion 17: La forma de dosificacion oral de la reivindicacion 16, en donde la forma de dosificacion comprende de 50 a 250 mg de ácido N-[8-(2-hidroxibenzoil) amino] caprílico o una sal farmacéuticamente aceptable del mismo, y de 0,5 a 2 mg de vitamina B12. Reivindicacion 18: Una forma de dosificacion oral que comprende: (a) un inhibidor de la bomba de protones; (b) la vitamina B1; (c) N-[8-(2-hidroxibenzoil) amino] caprilato sodico; (d) ácido folico. Reivindicacion 20: Una forma de dosificacion oral que comprende: (a) metformina; (b) la vitamina B12 (c) N-[8-(2-hidroxibenzoil) amino] caprilato sodico, y (d) de ácido fálico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30783610P | 2010-02-24 | 2010-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080292A1 true AR080292A1 (es) | 2012-03-28 |
Family
ID=44477007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100553A AR080292A1 (es) | 2010-02-24 | 2011-02-23 | Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20110207693A1 (es) |
| EP (2) | EP3028709B1 (es) |
| JP (3) | JP2013520511A (es) |
| KR (1) | KR20130026429A (es) |
| AR (1) | AR080292A1 (es) |
| AU (1) | AU2011220867B2 (es) |
| BR (1) | BR112012021401B1 (es) |
| CA (2) | CA2996757A1 (es) |
| CL (1) | CL2012002358A1 (es) |
| CO (1) | CO6602160A2 (es) |
| MX (1) | MX2012009914A (es) |
| NZ (2) | NZ602032A (es) |
| RU (1) | RU2576511C2 (es) |
| TW (1) | TWI590829B (es) |
| WO (1) | WO2011106378A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2925534T3 (es) | 2011-11-05 | 2022-10-18 | South Alabama Medical Science Found | Métodos, formulaciones y kits para reponer rápidamente los niveles de folato en mujeres |
| EP4299118A3 (en) | 2018-02-02 | 2024-04-10 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| TWI829687B (zh) * | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN111517980B (zh) * | 2020-05-14 | 2021-02-09 | 台州浦凯医药科技有限公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6274564B1 (en) * | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
| US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6117868A (en) * | 1998-09-16 | 2000-09-12 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
| NZ534409A (en) * | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| CA2402719C (en) * | 2000-03-21 | 2012-03-20 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| CA2445512C (en) * | 2001-04-25 | 2010-10-12 | Cobalz Limited | A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| TW200403052A (en) * | 2002-07-17 | 2004-03-01 | Novartis Ag | Use of organic compounds |
| RU2359698C2 (ru) * | 2002-09-13 | 2009-06-27 | Сайдекс, Инк. | Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина |
| DE10311089A1 (de) * | 2003-03-13 | 2004-09-23 | Roche Diagnostics Gmbh | Differenzialdiagnostik und Monitoring von Vitamin B12-, Vitamin B6- und Folsäure-Störungen mittels vier unabhängiger Messgrößen |
| PT1651248E (pt) * | 2003-07-11 | 2009-11-10 | Novartis Ag | Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada |
| US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
| SG153039A1 (en) * | 2004-05-06 | 2009-06-29 | Emisphere Tech Inc | Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate |
| WO2006020291A2 (en) * | 2004-08-02 | 2006-02-23 | Bebaas, Inc. | Vitamin b12 compositions |
| JP2008509933A (ja) * | 2004-08-13 | 2008-04-03 | エミスフェアー・テクノロジーズ・インク | 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤 |
| CN101103045B (zh) * | 2004-09-24 | 2015-11-25 | 安姆根有限公司 | 修饰的Fc分子 |
| US20060116334A1 (en) * | 2004-12-01 | 2006-06-01 | Curt Hendrix | Folate based composition for treatment of the cardiovascular system |
| CA2626029A1 (en) * | 2005-11-04 | 2007-05-18 | Genta Incorporated | Pharmaceutical gallium compositions and methods |
| BRPI0601834A (pt) * | 2006-03-30 | 2007-11-27 | Ricardo De Souza Pereira | suplementação dietética para curar ou regredir sintomas de refluxo gastroesofágico, gastrite e úlceras |
| DE102007005952A1 (de) * | 2007-02-06 | 2008-08-07 | BSH Bosch und Siemens Hausgeräte GmbH | Kältegerät mit an einer Schiene aufgehängten Fachböden |
| US7943163B2 (en) * | 2007-08-22 | 2011-05-17 | Response Scientific, Inc. | Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes |
| WO2009059188A1 (en) * | 2007-11-02 | 2009-05-07 | Emisphere Technologies, Inc. | Method of treating vitamin b12 deficiency |
-
2011
- 2011-02-23 KR KR1020127024905A patent/KR20130026429A/ko not_active Ceased
- 2011-02-23 CA CA2996757A patent/CA2996757A1/en not_active Abandoned
- 2011-02-23 JP JP2012555099A patent/JP2013520511A/ja active Pending
- 2011-02-23 TW TW100105996A patent/TWI590829B/zh not_active IP Right Cessation
- 2011-02-23 WO PCT/US2011/025864 patent/WO2011106378A2/en not_active Ceased
- 2011-02-23 EP EP15201219.1A patent/EP3028709B1/en active Active
- 2011-02-23 RU RU2012136176/15A patent/RU2576511C2/ru active
- 2011-02-23 NZ NZ602032A patent/NZ602032A/en not_active IP Right Cessation
- 2011-02-23 NZ NZ701274A patent/NZ701274A/en not_active IP Right Cessation
- 2011-02-23 AR ARP110100553A patent/AR080292A1/es not_active Application Discontinuation
- 2011-02-23 EP EP11747966.7A patent/EP2538945A4/en not_active Ceased
- 2011-02-23 CA CA2790708A patent/CA2790708A1/en not_active Abandoned
- 2011-02-23 BR BR112012021401A patent/BR112012021401B1/pt not_active IP Right Cessation
- 2011-02-23 US US13/033,118 patent/US20110207693A1/en not_active Abandoned
- 2011-02-23 MX MX2012009914A patent/MX2012009914A/es unknown
- 2011-02-23 AU AU2011220867A patent/AU2011220867B2/en not_active Ceased
-
2012
- 2012-08-24 CL CL2012002358A patent/CL2012002358A1/es unknown
- 2012-09-17 CO CO12159803A patent/CO6602160A2/es not_active Application Discontinuation
-
2015
- 2015-07-30 JP JP2015150644A patent/JP2015193660A/ja active Pending
- 2015-11-30 US US14/954,393 patent/US20160074420A1/en not_active Abandoned
-
2017
- 2017-03-07 JP JP2017042569A patent/JP2017101081A/ja active Pending
-
2020
- 2020-03-09 US US16/812,888 patent/US20200206247A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ701274A (en) | 2016-03-31 |
| US20160074420A1 (en) | 2016-03-17 |
| TWI590829B (zh) | 2017-07-11 |
| EP2538945A4 (en) | 2013-07-24 |
| JP2013520511A (ja) | 2013-06-06 |
| TW201200139A (en) | 2012-01-01 |
| CA2790708A1 (en) | 2011-09-01 |
| BR112012021401B1 (pt) | 2019-12-24 |
| CO6602160A2 (es) | 2013-01-18 |
| AU2011220867B2 (en) | 2014-05-15 |
| RU2576511C2 (ru) | 2016-03-10 |
| EP2538945A2 (en) | 2013-01-02 |
| US20110207693A1 (en) | 2011-08-25 |
| MX2012009914A (es) | 2013-03-05 |
| HK1225609A1 (en) | 2017-09-15 |
| WO2011106378A2 (en) | 2011-09-01 |
| KR20130026429A (ko) | 2013-03-13 |
| US20200206247A1 (en) | 2020-07-02 |
| RU2012136176A (ru) | 2014-03-27 |
| CL2012002358A1 (es) | 2012-12-14 |
| EP3028709A1 (en) | 2016-06-08 |
| WO2011106378A3 (en) | 2011-11-24 |
| CA2996757A1 (en) | 2011-09-01 |
| EP3028709B1 (en) | 2019-08-28 |
| JP2015193660A (ja) | 2015-11-05 |
| JP2017101081A (ja) | 2017-06-08 |
| AU2011220867A1 (en) | 2012-09-20 |
| NZ602032A (en) | 2014-11-28 |
| BR112012021401A2 (pt) | 2016-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA201270041A1 (ru) | Лечение рассеянного склероза лаквинимодом | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BR112015009504A2 (pt) | inibidores de rock | |
| RU2015126661A (ru) | Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата | |
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| EA200501105A1 (ru) | Фармацевтическая композиция | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| AR080292A1 (es) | Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| UY31826A (es) | Compuesto peptídico y su uso | |
| AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
| AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
| ES2746002T3 (es) | Aplicación de homogeneizado de larvas de zánganos adsorbido y de vitamina D3 o vitaminas del grupo d y/o metabolitos activos de las mismas para prevenir y tratar enfermedades víricas | |
| RU2010134265A (ru) | Способ лечения диспепсии у телят | |
| MX2015005486A (es) | Usos de bremelanotida en terapia para la disfuncion sexual femenina. | |
| AR114587A1 (es) | Formulaciones de epinefrina en aerosol | |
| RU2008140019A (ru) | Способ лечения и профилактики эндометритов у коров | |
| Boudewijns | Indoor-photosensitivity and alopecia: 3 case reports |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |